BXT-25 is predicted to oxygenate the mind and be monitored by Bioxytran’s FDA accredited medical system to hint all oxygen molecules
BOSTON, MASSACHUSETTS, July 8, 2024 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a scientific stage biotechnology firm creating medication to deal with stroke and Alzheimer’s illness, introduced that Bioxtran’s Science Advisor Prof. Avraham Mayevsky’s e-book titled Hyperbaric Oxygenation Mitochondrial Exercise and Mind Physiological Features was revealed by a publishing home, Springer. It’s obtainable by eBook or Hardcover. The e-book is straight tied to the Hypoxia platform know-how which makes use of the MDX Viewer as an analytical methodology, which is an FDA accredited system to measure tissue oxygenation. The system measures the consumption of oxygen molecules in tissues on a mobile degree. The output of the MDX Viewer is the Mind Metabolic Rating BMS, which is an important a part of the approval course of for Bioxytran’s acellular oxygen service (AOC) molecule referred to as BXT-25. Bioxytran plans on utilizing the BXT-25 in its scientific trials for ischemic stroke and Alzheimer’s illness sufferers as a approach to exchange hyperbaric oxygen remedy (HBOT).
https://hyperlink.springer.com/e-book/10.1007/978-3-031-49681-3
The e-book is a complete overview of the results of hyperbaric oxygen on mind features together with mitochondrial exercise. The MDX viewer is an FDA accredited medical system that measures tissue metabolic rating and its outcomes are cited many occasions all through the e-book. The outcomes from the MDX viewer supplied a strong basis upon which he was in a position to additional elucidate the connection between oxygenation and cerebral operate with respect to hyperbaric oxygenation remedy. The e-book additionally discusses the results of hyperbaric oxygen remedy on mind biochemical and physiological responses that may affect mitochondrial exercise, which is crucial for power manufacturing. The proof means that hyperbaric oxygen improves cerebral blood circulate and tissue oxygenation which finally ends in a optimistic affect on mind functioning and efficiency.
“BXT-25 is expected to oxygenate the brain and other human organs and tissues,” mentioned Avraham Mayevsky, Member of Bioxytran’s Medical Advisory Board. “One of the biggest challenges in in clinical trials is determining the efficacy of a drug. One of the most widely held beliefs in medicine is that increased mitochondrial activity at the cellular level means cells are working more efficiently and that ultimately leads to a demonstration of efficacy of a drug. The MDX viewer is an FDA approved device that monitors oxygenation in real time and is so sensitive, that it’s conceivable future applications could be used as an endpoint of efficacy. Drugs capable of treating diseases will ultimately impact they body by increasing the BMS. This means that if a patient baseline BMS is established and then an efficacious drug is introduced the BMS will rise. Conversely if a drug is tested on a person who experiences side effects, its likely the BMS will go down. Since BXT-25 is essentially a miniaturized oxygen carrier we would expect to see favorable increases in BMS. Coupling the MDX Viewer in clinical trials with drugs like BXT-25 could significantly shorten the clinical trial processes an demonstrate efficacy on a cellular level using an unbiased biomarker instead of surrogate biomarkers to demonstrate efficacy. Ultimately, I see this will shorten the time for FDA approval as a universal oxygen carrier for tissue oxygenation.”
About Bioxytran, Inc.
Bioxytran, Inc. is a scientific stage biotechnology firm creating a drug to deal with stroke in an early stage and Alzheimer’s illness by delivering oxygen with a molecule that’s 5000 occasions smaller than a purple blood cell. Extra info will be discovered at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Ahead-Trying Statements
This press launch consists of forward-looking statements as outlined below federal regulation, together with these associated to the efficiency of know-how described on this press launch. These forward-looking statements are typically recognized by the phrases “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and related expressions, though not all forward-looking statements comprise these figuring out phrases. Such statements are topic to vital dangers, assumptions and uncertainties. Identified materials elements that might trigger Bioxytran’s precise outcomes to vary materially from the outcomes contemplated by such forward-looking statements are described within the forward-looking statements and danger elements within the Firm’s Annual Report on Kind 10-Okay for the fiscal 12 months ended December 31, 2023 and people danger elements set forth from time-to-time in different filings with the Securities and Change Fee. Bioxytran undertakes no obligation to appropriate or replace any forward-looking assertion, whether or not on account of new info, future occasions, or in any other case, besides to the extent required below federal securities legal guidelines.
Media Contact:
david.platt@bioxytraninc.com
6175102539
www.bioxytrantinc.com
Bioxytran
David Platt
